Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moos...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moos...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moo...
Welcome to where we thrive together Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives. Join us Resource links About Novartis Healthcare professionals Patients and caregivers Pipeline ...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moo...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Mar 19, 2025 Media Release New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad ...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moo...
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Mar 31, 2025 Media Release Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moos...
Welcome to where we thrive together Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives. Join us Resource links About Novartis Healthcare professionals Patients and caregivers Pipeline ...
Welcome to where we thrive together Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives. Join us Resource links About Novartis Healthcare professionals Patients and caregivers Pipeline ...